20
Participants
Start Date
September 30, 2010
Primary Completion Date
September 30, 2013
Study Completion Date
September 30, 2015
Bortezomib
"INDUCTION THERAPY: 1.3 mg/m2, IV (in the vein) on day 1， 4， 8， 11 of each 28 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.~MAINTENANCE THERAPY: 1.3 mg/m2, IV (in the vein) on day 1， 4， 8， 11 of each 28 day cycle. 4 Cycles: interval between every two cycles for 6 months, until progression or unacceptable toxicity develops."
Liposome doxorubicin
INDUCTION THERAPY: 30 mg/m2, IV (in the vein) on day 4 of each 28 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.
Dexamethasone
"INDUCTION THERAPY: 40 mg/d, IV (in the vein) on day 1- 4 of each 28 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.~MAINTENANCE THERAPY: 40 mg/d, IV (in the vein) on day 1- 4 of each 28 day cycle. 4 Cycles: interval between every two cycles for 6 months, until progression or unacceptable toxicity develops."
RECRUITING
Beijing Clinical Service Center, Beijing
Lead Sponsor
Harbin Hematology and Oncology Institute
OTHER
Shanghai Changzheng Hospital
OTHER
Chinese PLA General Hospital
OTHER
307 Hospital of PLA
OTHER
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
OTHER
Beijing Chao Yang Hospital
OTHER
Henan Provincial People's Hospital
OTHER
Peking University Third Hospital
OTHER
Clinical Service, China
INDUSTRY